Teun van Gelder

21.6k total citations
455 papers, 15.5k citations indexed

About

Teun van Gelder is a scholar working on Transplantation, Pediatrics, Perinatology and Child Health and Surgery. According to data from OpenAlex, Teun van Gelder has authored 455 papers receiving a total of 15.5k indexed citations (citations by other indexed papers that have themselves been cited), including 236 papers in Transplantation, 124 papers in Pediatrics, Perinatology and Child Health and 106 papers in Surgery. Recurrent topics in Teun van Gelder's work include Renal Transplantation Outcomes and Treatments (235 papers), Pharmacological Effects and Toxicity Studies (101 papers) and Neurological Complications and Syndromes (58 papers). Teun van Gelder is often cited by papers focused on Renal Transplantation Outcomes and Treatments (235 papers), Pharmacological Effects and Toxicity Studies (101 papers) and Neurological Complications and Syndromes (58 papers). Teun van Gelder collaborates with scholars based in Netherlands, United States and Germany. Teun van Gelder's co-authors include Dennis A. Hesselink, Willem Weimar, Ron H. N. van Schaik, Ron A. A. Mathôt, Arnold G. Vulto, Brenda C. M. de Winter, Ron H.J. Mathijssen, Rachida Bouamar, Laure Elens and Reinier M. van Hest and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Teun van Gelder

438 papers receiving 15.2k citations

Peers

Countries citing papers authored by Teun van Gelder

Since Specialization

Citations

This map shows the geographic impact of Teun van Gelder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Teun van Gelder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Teun van Gelder more than expected).

Fields of papers citing papers by Teun van Gelder

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Teun van Gelder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Teun van Gelder. The network helps show where Teun van Gelder may publish in the future.

Co-authorship network of co-authors of Teun van Gelder

This figure shows the co-authorship network connecting the top 25 collaborators of Teun van Gelder. A scholar is included among the top collaborators of Teun van Gelder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Teun van Gelder. Teun van Gelder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Effect of CYP3A4 Methylation on Tacrolimus Pharmacokinetics 2025 ·Therapeutic Drug Monitoring ·(unknown), (unknown), Costanza L. Vallerga, Dirk Jan A. R. Moes, (unknown), Jesse J. Swen, Minneke J. Coenraad, Teun van Gelder	0
2	Population Pharmacokinetics of Trimethoprim/Sulfamethoxazole: Dosage Optimization for Patients with Renal Insufficiency or Receiving Continuous Renal Replacement Therapy 2024 ·Clinical Pharmacology & Therapeutics ·(unknown), (unknown), Erik B. Wilms, Leo G. Visser, Daan J. Touw, Brenda C. M. de Winter, Mark de Boer, Judith van Paassen, Charlotte H. S. B. van den Berg, Joffrey van Prehn, Teun van Gelder, Dirk Jan A. R. Moes	1
3	Should we abandon therapeutic drug monitoring of tacrolimus in whole blood and move to intracellular concentration measurements? 2023 ·British Journal of Clinical Pharmacology ·Suwasin Udomkarnjananun, (unknown), Brenda C. M. de Winter, Teun van Gelder, Dennis A. Hesselink	10
4	Development and Bioequivalence of 3D‐Printed Medication at the Point‐of‐Care: Bridging the Gap Toward Personalized Medicine 2023 ·Clinical Pharmacology & Therapeutics ·(unknown), (unknown), Dina M. Kweekel, Brenda C. M. de Winter, Jesse J. Swen, P.P.H. Le Brun, (unknown), Teun van Gelder, Henk‐Jan Guchelaar, Dirk Jan A. R. Moes, Kirsten J. M. Schimmel	23
5	Towards Fixed Dosing of Tocilizumab in ICU-Admitted COVID-19 Patients: Results of an Observational Population Pharmacokinetic and Descriptive Pharmacodynamic Study 2021 ·Clinical Pharmacokinetics ·Dirk Jan A. R. Moes, David J. van Westerloo, Sandra M. Arend, Jesse J. Swen, Annick de Vries, Henk‐Jan Guchelaar, Simone A. Joosten, Mark de Boer, Teun van Gelder, Judith van Paassen	10
6	Combining Sorafenib and Immunosuppression in Liver Transplant Recipients with Hepatocellular Carcinoma 2021 ·Pharmaceuticals ·Koen G. A. M. Hussaarts, Leni van Doorn, Sander Bins, Dave Sprengers, Peter de Bruijn, Roelof W. F. van Leeuwen, Stijn L.W. Koolen, Teun van Gelder, Ron H.J. Mathijssen	8
7	Severe COVID-19 in a renal transplant recipient: A focus on pharmacokinetics 2020 ·American Journal of Transplantation ·Soufian Meziyerh, Tom C. Zwart, (unknown), (unknown), Teun van Gelder, Ian P.J. Alwayn, Johan W. de Fijter, Marlies E. J. Reinders, Dirk Jan A. R. Moes, Aiko P. J. de Vries	44
8	Influence of Probenecid on the Pharmacokinetics and Pharmacodynamics of Sorafenib 2020 ·Pharmaceutics ·Koen G. A. M. Hussaarts, Leni van Doorn, Karel Eechoute, Jeffrey Damman, Qiang Fu, (unknown), Eric D. Eisenmann, Alice A. Gibson, Esther Oomen‐de Hoop, Peter de Bruijn, Sharyn D. Baker, Stijn L.W. Koolen, Teun van Gelder, Roelof W. F. van Leeuwen, Ron H.J. Mathijssen, Alex Sparreboom, Sander Bins	10
9	Psychotropic drug concentrations and clinical outcomes in children and adolescents: a systematic review 2020 ·Expert Opinion on Drug Safety ·Sanne Kloosterboer, (unknown), Jana Stojanova, Karin Egberts, Manfred Gerlach, Gwen Dieleman, Manon H. J. Hillegers, (unknown), Teun van Gelder, Bram Dierckx, Birgit C. P. Koch	13
10	Comparison of the Impact of Pharmacogenetic Variability on the PK of Slow Release and Immediate Release Tacrolimus Formulations 2020 ·Genes ·Teun van Gelder, (unknown), Dirk Jan A. R. Moes, Jesse J. Swen	5
11	The Risk of QTc-Interval Prolongation in Breast Cancer Patients Treated with Tamoxifen in Combination with Serotonin Reuptake Inhibitors 2019 ·Pharmaceutical Research ·Koen G. A. M. Hussaarts, (unknown), Lisette Binkhorst, Esther Oomen‐de Hoop, Roelof W. F. van Leeuwen, Robbert J. van Alphen, (unknown), Natasja M.S. de Groot, Ron H.J. Mathijssen, Teun van Gelder	9
12	Impact of Curcumin (with or without Piperine) on the Pharmacokinetics of Tamoxifen 2019 ·Cancers ·Koen G. A. M. Hussaarts, Daan P. Hurkmans, Esther Oomen‐de Hoop, (unknown), (unknown), Robbert J. van Alphen, (unknown), (unknown), (unknown), Ron H. N. van Schaik, Teun van Gelder, Agnes Jager, Roelof W. F. van Leeuwen, Ron H.J. Mathijssen	34
13	A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients 2018 ·British Journal of Clinical Pharmacology ·Louise M. Andrews, Dennis A. Hesselink, Ron H. N. van Schaik, Teun van Gelder, Johan W. de Fijter, Núria Lloberas, Laure Elens, Dirk Jan A. R. Moes, Brenda C. M. de Winter	75
14	Kidney transplant patients’ attitudes towards self-management support: A Q-methodological study 2015 ·Patient Education and Counseling ·(unknown), Mirjam Tielen, A.L. van Staa, (unknown), Teun van Gelder, Stefan P. Berger, Jan J.V. Busschbach, Michiel G.H. Betjes, Willem Weimar, Emma K. Massey	24
15	Attitudes to Medication after Kidney Transplantation and Their Association with Medication Adherence and Graft Survival: A 2-Year Follow-Up Study 2014 ·SHILAP Revista de lepidopterología ·Mirjam Tielen, Job van Exel, Mirjam Laging, Denise K. Beck, (unknown), Teun van Gelder, Michiel G.H. Betjes, Willem Weimar, Emma K. Massey	69
16	How Delayed Graft Function Impacts Exposure to Mycophenolic Acid in Patients After Renal Transplantation 2011 ·Therapeutic Drug Monitoring ·Teun van Gelder, Hélio Tedesco‐Silva, Johan W. de Fijter, Klemens Budde, Dirk Kuypers, Richard D. Mamelok, Victor W. Armstrong, Michael Oellerich	12
17	A novel risk assessment tool for rejection and infection to individually tailor immunosuppression in renal transplantation 2009 ·Lund University Publications (Lund University) ·Thomas Fehr, Henrik Ekberg, Teun van Gelder, Corrado Bernasconi, (unknown), Marc Schiesser	1
18	Renal graft survival in native and non-native European recipients 1999 ·Transplant International ·Joke I. Roodnat, Robert Zietse, J. Rischen-Vos, Teun van Gelder, Paul Mulder, Jan N.M. IJzermans, Willem Weimar	7
19	Renal graft survival in native and non-native European recipients 1999 ·Transplant International ·Joke I. Roodnat, Robert Zietse, J. Rischen-Vos, Teun van Gelder, Paul Mulder, Jan N.M. IJzermans, Willem Weimar	9
20	Prognostic factors and survival in malignant pleural mesothelioma 1994 ·European Respiratory Journal ·Teun van Gelder, (unknown), (unknown)	57

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact